RU2005129995A - Производные 3-(2-фенилоксазол-4-илметокси) циклогексилметоксиуксусной кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза - Google Patents
Производные 3-(2-фенилоксазол-4-илметокси) циклогексилметоксиуксусной кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза Download PDFInfo
- Publication number
- RU2005129995A RU2005129995A RU2005129995/04A RU2005129995A RU2005129995A RU 2005129995 A RU2005129995 A RU 2005129995A RU 2005129995/04 A RU2005129995/04 A RU 2005129995/04A RU 2005129995 A RU2005129995 A RU 2005129995A RU 2005129995 A RU2005129995 A RU 2005129995A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- phenyl
- aryl
- heteroaryl
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims 3
- -1 2-Phenyloxazole-4-ylmethoxy Chemical group 0.000 title claims 2
- RVIVELDVEOFQJR-UHFFFAOYSA-N 2-(cyclohexylmethoxy)acetic acid Chemical class OC(=O)COCC1CCCCC1 RVIVELDVEOFQJR-UHFFFAOYSA-N 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 230000002265 prevention Effects 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10308355A DE10308355A1 (de) | 2003-02-27 | 2003-02-27 | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE10308355.3 | 2003-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005129995A true RU2005129995A (ru) | 2006-01-27 |
Family
ID=32920629
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005129995/04A RU2005129995A (ru) | 2003-02-27 | 2004-02-19 | Производные 3-(2-фенилоксазол-4-илметокси) циклогексилметоксиуксусной кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза |
| RU2005129992/04A RU2005129992A (ru) | 2003-02-27 | 2004-02-19 | Производные 4-(2-фенилоксазол-4-илметокси) циклогексилокси) бутановой кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза |
| RU2005130002/04A RU2005130002A (ru) | 2003-02-27 | 2004-02-19 | Производные 3-метил-2-(2-фенилоксазол-4-илметокси)циклогексанкарбониламино)масляной кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005129992/04A RU2005129992A (ru) | 2003-02-27 | 2004-02-19 | Производные 4-(2-фенилоксазол-4-илметокси) циклогексилокси) бутановой кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза |
| RU2005130002/04A RU2005130002A (ru) | 2003-02-27 | 2004-02-19 | Производные 3-метил-2-(2-фенилоксазол-4-илметокси)циклогексанкарбониламино)масляной кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза |
Country Status (34)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| US7399777B2 (en) * | 2001-08-31 | 2008-07-15 | Sanofi-Aventis Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals |
| DE10308353A1 (de) * | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102004038403B4 (de) * | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten |
| DE102004039509B4 (de) * | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102004039533B4 (de) * | 2004-08-14 | 2006-09-28 | Sanofi-Aventis Deutschland Gmbh | Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE102004039532B4 (de) * | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE102004060227B3 (de) * | 2004-12-15 | 2006-07-20 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten |
| GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| KR101398715B1 (ko) | 2006-08-10 | 2014-05-27 | 가부시키가이샤 미모잭스 | 아카시아속 나무 껍질 유래물을 함유하는 혈당 강하 조성물 |
| JP5340287B2 (ja) | 2007-08-16 | 2013-11-13 | ソルヴェイ（ソシエテ アノニム） | ４−フルオロ置換３−オキソ−アルカン酸のエステル類の調製方法 |
| ES2574159T3 (es) | 2008-02-29 | 2016-06-15 | Nissan Chemical Industries, Ltd. | Proceso para la producción de compuesto de tiofeno e intermedio del mismo |
| US7615661B2 (en) * | 2008-03-12 | 2009-11-10 | International Flavors & Fragrances Inc. | Thioester compounds and their use in fragrance or flavor applications |
| BR112020011659A2 (pt) | 2017-12-13 | 2020-11-17 | Canon Kabushiki Kaisha | cartucho e aparelho de formação de imagem |
| CN109810071B (zh) * | 2019-03-28 | 2023-04-21 | 中国科学院成都生物研究所 | 一种miRNA生物合成抑制剂 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2663464B1 (fr) * | 1990-06-19 | 1992-09-11 | Commissariat Energie Atomique | Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication. |
| IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| JP3144624B2 (ja) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| IL125071A0 (en) | 1996-01-17 | 1999-01-26 | Novo Nordisk As | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives their preparation and use |
| HU227021B1 (en) | 1996-08-30 | 2010-05-28 | Novo Nordisk As | Glp-1 derivatives |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| JP4339402B2 (ja) | 1996-12-31 | 2009-10-07 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 新規なヘテロ環化合物、これらの製造方法及びこれらを含有する薬学的組成物、並びに糖尿病及び関連疾患の治療におけるこれらの使用 |
| DE19726167B4 (de) * | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| CA2294830A1 (en) | 1997-07-16 | 1999-01-28 | John Bondo Hansen | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| CO4970713A1 (es) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
| ATE451346T1 (de) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| KR100613175B1 (ko) * | 1998-08-27 | 2006-08-17 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제 |
| DE19845405C2 (de) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
| GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
| DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| WO2000063208A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| US6908926B1 (en) * | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| DE60027420T2 (de) * | 1999-04-28 | 2006-11-16 | Aventis Pharma Deutschland Gmbh | Tri-aryl-säurederivate als ppar rezeptor liganden |
| DK1177187T3 (da) | 1999-04-28 | 2007-10-15 | Sanofi Aventis Deutschland | Diarylsyrederivater som PPAR-receptorligander |
| AU4808300A (en) | 1999-04-30 | 2000-11-17 | Neurogen Corporation | 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands |
| GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
| ATE333448T1 (de) | 1999-06-18 | 2006-08-15 | Merck & Co Inc | Arylthiazolidinedione und aryloxa zolidinedion- derivate |
| WO2001004146A2 (en) | 1999-07-09 | 2001-01-18 | Cohesion Technologies, Inc. | Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof |
| EP1204654B1 (en) | 1999-07-29 | 2003-07-23 | Eli Lilly And Company | Benzofurylpiperazines: 5-ht2c serotonin receptor agonists |
| IL148148A0 (en) * | 1999-09-01 | 2002-09-12 | Aventis Pharma Gmbh | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
| TWI302149B (en) | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| SE9904413D0 (sv) | 1999-12-03 | 1999-12-03 | Astra Ab | Comminuted form |
| WO2001040171A1 (en) | 1999-12-03 | 2001-06-07 | Astrazeneca Ab | Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid |
| HU229042B1 (en) | 2000-03-31 | 2013-07-29 | Prosidion Ltd | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| CZ20023502A3 (cs) | 2000-04-25 | 2003-06-18 | Kyorin Pharmaceutical Co., Ltd. | Nová stabilní krystalická forma thiazolidionového derivátu a způsob jeho přípravy |
| CN1430603A (zh) | 2000-04-28 | 2003-07-16 | 旭化成株式会社 | 新型双环化合物 |
| BR0110638A (pt) | 2000-05-11 | 2003-03-25 | Bristol Myers Squibb Co | Análogos de tetraidroisoquinolina úteis como secretagogos de hormÈnio do crescimento |
| JP2003534377A (ja) | 2000-05-30 | 2003-11-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬 |
| WO2001094300A1 (de) * | 2000-06-09 | 2001-12-13 | Aventis Pharma Deutschland Gmbh | Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| DE10038709A1 (de) | 2000-08-09 | 2002-02-28 | Aventis Pharma Gmbh | Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen |
| EP1182251A1 (en) * | 2000-08-11 | 2002-02-27 | Yissum Research Development Company of the Hebrew University of Jerusalem | Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB |
| US6982278B2 (en) | 2000-08-23 | 2006-01-03 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
| WO2002016331A1 (en) * | 2000-08-23 | 2002-02-28 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| JPWO2002046146A1 (ja) | 2000-12-05 | 2004-04-08 | 杏林製薬株式会社 | 置換カルボン酸誘導体 |
| GB0031103D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| DE50111751D1 (de) | 2000-12-21 | 2007-02-08 | Sanofi Aventis Deutschland | Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen |
| ATE370130T1 (de) * | 2000-12-25 | 2007-09-15 | Ono Pharmaceutical Co | Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten |
| WO2002064549A1 (en) * | 2001-02-15 | 2002-08-22 | Pfizer Products Inc. | Ppar agonists |
| PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| EA200400011A1 (ru) * | 2001-06-07 | 2004-06-24 | Эли Лилли Энд Компани | Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar) |
| DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| WO2003005025A1 (en) | 2001-07-03 | 2003-01-16 | Biovitrum Ab | Methods for identifying compounds modulating the activity of ppar-gamma |
| FR2827859B1 (fr) | 2001-07-30 | 2005-09-23 | Lipha | Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete |
| EE05418B1 (et) | 2001-08-31 | 2011-06-15 | Aventis Pharma Deutschland Gmbh | Diarltskloalklderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim |
| EP1474385B1 (en) | 2002-02-05 | 2009-06-10 | Eli Lilly And Company | Urea linker derivatives for use as ppar modulators |
| DE10215908B4 (de) | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
| DE10215907A1 (de) | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
| DE10225635C1 (de) | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
| PL374860A1 (en) | 2002-07-09 | 2005-11-14 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| US7148246B2 (en) * | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
-
2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/de not_active Withdrawn
-
2004
- 2004-02-19 DK DK04712503T patent/DK1599455T3/da active
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/zh not_active Expired - Fee Related
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/es active IP Right Grant
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/de active Application Filing
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/zh not_active Expired - Fee Related
- 2004-02-19 EP EP04712494A patent/EP1599453B1/de not_active Expired - Lifetime
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/ja active Pending
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/pt not_active IP Right Cessation
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/zh not_active Expired - Fee Related
- 2004-02-19 ES ES04712503T patent/ES2329366T3/es not_active Expired - Lifetime
- 2004-02-19 PT PT04712503T patent/PT1599455E/pt unknown
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/ru not_active Application Discontinuation
- 2004-02-19 EP EP04712490A patent/EP1599452B1/de not_active Expired - Lifetime
- 2004-02-19 PL PL378130A patent/PL378130A1/pl not_active Application Discontinuation
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/de not_active Expired - Lifetime
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/de active IP Right Grant
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/ru not_active Application Discontinuation
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-19 AT AT04712503T patent/ATE435217T1/de not_active IP Right Cessation
- 2004-02-19 AT AT04712490T patent/ATE365159T1/de not_active IP Right Cessation
- 2004-02-19 PL PL378437A patent/PL378437A1/pl not_active Application Discontinuation
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/pt not_active IP Right Cessation
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/ja active Pending
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/de active Application Filing
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/ko not_active Application Discontinuation
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/ko not_active Application Discontinuation
- 2004-02-19 EP EP04712503A patent/EP1599455B1/de not_active Expired - Lifetime
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/pt not_active IP Right Cessation
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/ru not_active Application Discontinuation
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/sr unknown
- 2004-02-19 DK DK04712494T patent/DK1599453T3/da active
- 2004-02-19 PT PT04712494T patent/PT1599453E/pt unknown
- 2004-02-19 PT PT04712490T patent/PT1599452E/pt unknown
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/es active IP Right Grant
- 2004-02-19 DK DK04712490T patent/DK1599452T3/da active
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/ja active Pending
- 2004-02-19 AT AT04712494T patent/ATE430738T1/de not_active IP Right Cessation
- 2004-02-19 ES ES04712490T patent/ES2287700T3/es not_active Expired - Lifetime
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/de not_active Expired - Lifetime
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/ko not_active Application Discontinuation
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/de not_active Expired - Lifetime
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/es active IP Right Grant
- 2004-02-19 PL PL377735A patent/PL377735A1/pl not_active Application Discontinuation
- 2004-02-19 ES ES04712494T patent/ES2326418T3/es not_active Expired - Lifetime
- 2004-02-25 TW TW093104705A patent/TW200510352A/zh unknown
- 2004-02-25 TW TW093104704A patent/TW200500349A/zh unknown
- 2004-02-25 TW TW093104697A patent/TW200508210A/zh unknown
- 2004-02-27 UY UY28209A patent/UY28209A1/es unknown
- 2004-02-27 US US10/789,017 patent/US7335671B2/en active Active
- 2004-02-27 UY UY28210A patent/UY28210A1/es unknown
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/es unknown
- 2004-02-27 AR ARP040100629A patent/AR043427A1/es not_active Application Discontinuation
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/es unknown
- 2004-02-27 US US10/788,996 patent/US7259177B2/en active Active
- 2004-02-27 AR ARP040100635A patent/AR043432A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/es unknown
- 2004-02-27 AR ARP040100636A patent/AR043433A1/es not_active Application Discontinuation
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/es not_active Application Discontinuation
- 2004-06-09 SA SA04250153A patent/SA04250153A/ar unknown
-
2005
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-26 MA MA28465A patent/MA27742A1/fr unknown
- 2005-08-26 CO CO05085499A patent/CO5690578A2/es not_active Application Discontinuation
- 2005-08-26 MA MA28459A patent/MA27736A1/fr unknown
- 2005-08-26 CO CO05085508A patent/CO5690580A2/es not_active Application Discontinuation
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 HR HR20050743A patent/HRP20050743A2/xx not_active Application Discontinuation
- 2005-08-26 MA MA28460A patent/MA27737A1/fr unknown
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/es unknown
- 2005-08-26 HR HR20050744A patent/HRP20050744A2/xx not_active Application Discontinuation
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/es unknown
- 2005-08-26 HR HR20050742A patent/HRP20050742A2/xx not_active Application Discontinuation
- 2005-09-22 NO NO20054408A patent/NO20054408L/no unknown
- 2005-09-22 NO NO20054398A patent/NO20054398L/no unknown
- 2005-09-22 NO NO20054396A patent/NO20054396L/no unknown
-
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
-
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005129995A (ru) | Производные 3-(2-фенилоксазол-4-илметокси) циклогексилметоксиуксусной кислоты и родственные соединения в качестве модуляторов ppar для лечения диабета типа 2 и атеросклероза | |
| RU2009126745A (ru) | Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств | |
| JP2003501474A5 (US07365084-20080429-C00043.png) | ||
| RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
| RU2006106231A (ru) | Замещенные производные диоксида тиазолбензоизотиазола, способ их получения и их применение | |
| RU2000131183A (ru) | Производные оксииминоалкановой кислоты | |
| TW200617001A (en) | Novel glucitol derivative, its prodrug, their salt and diabetic therapeutic agent containing the same | |
| RU2011114982A (ru) | Модуляторы нмда-рецептора и их применения | |
| CA2422698A1 (en) | Indoline derivatives and their use as 5-ht2 receptor ligands | |
| JP5926272B2 (ja) | Ｗｎｔ経路のアンタゴニストとしてのクロメン誘導体及びそれらの類似体 | |
| RU2001111817A (ru) | Арилзамещенные производные пропаноламина, способ их получения, содержащие эти соединения лекарственные средства и их применение | |
| RU2005129999A (ru) | Диарилциклоалкильные производные, способы их получения и их применение в качестве лекарственного средства | |
| CN109641898A (zh) | 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物 | |
| CN102471271A (zh) | 杂环磺酰胺，其用途及药学组合物 | |
| JP2007500145A5 (US07365084-20080429-C00043.png) | ||
| RU98106112A (ru) | Производные пропаноламина, способы их получения, лекарственные средства, содержащие эти соединения и их применение | |
| JP6569661B2 (ja) | 選択的ｅｐ２アゴニスト活性を有する化合物 | |
| RU2004118423A (ru) | Производные бензотиазола в качестве лигандов рецептора аденозина | |
| CN104583201A (zh) | 作为用于在治疗ep4介导的疾病和病状中使用的ep4受体选择性激动剂的二氟内酰胺化合物 | |
| KR900004659A (ko) | α,α-이치환 N- 시클로알킬알킬 벤질아민, 이들의 제조 방법, 의약품으로서 이들의 용도 및 이들의 합성 중간체 | |
| RU2005110921A (ru) | N-замещенные 1н-индол-5-пропионовые кислоты в качестве предшественников агонистов, используемых для лечения диабета | |
| JP2003513075A5 (US07365084-20080429-C00043.png) | ||
| RU2005130005A (ru) | 1,3-замещенные циклоалкильные производные с кислотными, чаще всего гетероциклическими группами, способы их получения и их применение в качестве лекарственных средств | |
| CN1186020C (zh) | 用于提高突触应答的酰基苯并噁嗪 | |
| RU2005130004A (ru) | Арилциклоалкильные производные с разветвленными боковыми цепями в качестве модуляторов рецепторов ppar, способы их получения и их применение в качестве лекарственных средств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20070314 |